[
  {
    "ts": null,
    "headline": "Jim Cramer Notes That “People Are Staying Away From” Johnson & Johnson",
    "summary": "Cramer noted that investors are skirting Johnson & Johnson (NYSE:JNJ) because of worries regarding Robert Kennedy Jr., as he commented: “Or let’s consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises of any pharmaceutical […]",
    "url": "https://finnhub.io/api/news?id=73f880eab400bf532e636a91b80d298b851658adfa2325c8406bcd32f0e0baa7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747422499,
      "headline": "Jim Cramer Notes That “People Are Staying Away From” Johnson & Johnson",
      "id": 134567798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Cramer noted that investors are skirting Johnson & Johnson (NYSE:JNJ) because of worries regarding Robert Kennedy Jr., as he commented: “Or let’s consider Johnson & Johnson, triple A balance sheet, many drugs in the pipeline, one of the best-run companies in America, if not the world, with perhaps the most billion-dollar franchises of any pharmaceutical […]",
      "url": "https://finnhub.io/api/news?id=73f880eab400bf532e636a91b80d298b851658adfa2325c8406bcd32f0e0baa7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Turnaround Story Is Stronger Than You Think",
    "summary": "Pfizer's Turnaround Story Is Stronger Than You Think",
    "url": "https://finnhub.io/api/news?id=f1aa39358b70fbcabefaa095b1113b67f395143069dd178c847bce24ceee8311",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747405928,
      "headline": "Pfizer's Turnaround Story Is Stronger Than You Think",
      "id": 134500844,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f1aa39358b70fbcabefaa095b1113b67f395143069dd178c847bce24ceee8311"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=76ee267ffc144568c9762d1888e841b7ed5e306dbd81bb41a84a1dc97808bb98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747402811,
      "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
      "id": 134498596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=76ee267ffc144568c9762d1888e841b7ed5e306dbd81bb41a84a1dc97808bb98"
    }
  },
  {
    "ts": null,
    "headline": "Dow up 120 points on gains in shares of 3M, Nike",
    "summary": "Dow up 120 points on gains in shares of 3M, Nike",
    "url": "https://finnhub.io/api/news?id=3d0f6aa9db6e6adc62805817899bbe7e254261394e57c8e1794505445d6ee6b7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747398240,
      "headline": "Dow up 120 points on gains in shares of 3M, Nike",
      "id": 134501886,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Dow up 120 points on gains in shares of 3M, Nike",
      "url": "https://finnhub.io/api/news?id=3d0f6aa9db6e6adc62805817899bbe7e254261394e57c8e1794505445d6ee6b7"
    }
  },
  {
    "ts": null,
    "headline": "Uk's MHRA Approved Guselkumab (Tremfya) To Treat Crohn'S Disease And Ulcerative Colitis",
    "summary": "May 16 - UK'S MHRA: * UK'S MHRA: APPROVED GUSELKUMAB TO TREAT CROHN’SDISEASE AND ULCERATIVE COLITIS ...",
    "url": "https://finnhub.io/api/news?id=47425457fb4abfbc5b209431546c486efdeaeac26f231b778e3833fa547d3920",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747397237,
      "headline": "Uk's MHRA Approved Guselkumab (Tremfya) To Treat Crohn'S Disease And Ulcerative Colitis",
      "id": 134498244,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "May 16 - UK'S MHRA: * UK'S MHRA: APPROVED GUSELKUMAB TO TREAT CROHN’SDISEASE AND ULCERATIVE COLITIS ...",
      "url": "https://finnhub.io/api/news?id=47425457fb4abfbc5b209431546c486efdeaeac26f231b778e3833fa547d3920"
    }
  }
]